Fundamental analysis of Boston Scientific Corp

Reading the numbers

On average over recent years, earnings per share grew 67.2% a year and revenue advanced 16.1% a year.

On profitability, Boston Scientific Corp shows a net margin of 17.3%, a gross margin of 69.2%, an ROE of 13.8%.

Its financial health shows net debt of 0.65 times its EBITDA and a free cash flow margin of 16.9%.

Adding up growth, profitability and financial strength, the traffic light gives BSX a fundamental quality of 89 out of 100. To also know whether it's cheap or expensive, the price is missing: enter it in the tool and you'll get the valuation verdict (P/E against its sector).

The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.